αGalCer-RBD

αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain

Product Specifications

UNSPSC

12352005

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/αgalcer-rbd.html

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@H]([C@H](O[C@@H]([C@@H]1O)OC[C@@H]([C@@H]([C@@H](CCCCCCCCCCCCCC)O)O)NC(C#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC)=O)CNC(COCCOCCOCCNC(CON)=O)=O)O.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]

Molecular Formula

C60H118N4O14

Molecular Weight

1119.60

References & Citations

[1]Wang J, et al. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J Med Chem. 2022;65 (3) :2558-2570.